Reported Earnings • May 15
First quarter 2026 earnings released: EPS: kr0.005 (vs kr0.054 loss in 1Q 2025) First quarter 2026 results: EPS: kr0.005 (up from kr0.054 loss in 1Q 2025). Revenue: kr16.7m (up 9.3% from 1Q 2025). Net income: kr1.21m (up kr13.5m from 1Q 2025). Profit margin: 7.2% (up from net loss in 1Q 2025). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. New Risk • May 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (kr101.4m market cap, or US$10.9m). Tillkännagivande • Apr 30
IDL Diagnostics AB (publ), Annual General Meeting, May 28, 2026 IDL Diagnostics AB (publ), Annual General Meeting, May 28, 2026, at 11:00 W. Europe Standard Time. Location: company`s premises at karlsbodavagen 39 in bromma, Sweden Reported Earnings • Mar 01
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: kr0.053 loss per share (improved from kr0.18 loss in FY 2024). Revenue: kr53.1m (down 7.5% from FY 2024). Net loss: kr12.2m (loss narrowed 71% from FY 2024). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 50%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Breakeven Date Change • Feb 04
Forecast to breakeven in 2027 The analyst covering IDL Diagnostics expects the company to break even for the first time. New forecast suggests losses will reduce by 66% per year to 2026. The company is expected to make a profit of kr3.00m in 2027. Average annual earnings growth of 103% is required to achieve expected profit on schedule. Tillkännagivande • Nov 12
IDL Diagnostics AB (publ) to Report Fiscal Year 2025 Final Results on Apr 22, 2026 IDL Diagnostics AB (publ) announced that they will report fiscal year 2025 final results on Apr 22, 2026 Tillkännagivande • Oct 23
IDL Diagnostics AB (publ) to Report Q3, 2025 Results on Nov 12, 2025 IDL Diagnostics AB (publ) announced that they will report Q3, 2025 results on Nov 12, 2025 New Risk • Sep 15
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr92.1m (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (kr92.1m market cap, or US$9.94m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr9.6m net loss in 2 years). Share price has been volatile over the past 3 months (9.4% average weekly change). Breakeven Date Change • Aug 26
Forecast to breakeven in 2027 The analyst covering IDL Diagnostics expects the company to break even for the first time. New forecast suggests losses will reduce by 30% per year to 2026. The company is expected to make a profit of kr2.00m in 2027. Average annual earnings growth of 71% is required to achieve expected profit on schedule. Reported Earnings • Aug 22
Second quarter 2025 earnings released: kr0.06 loss per share (vs kr0.057 loss in 2Q 2024) Second quarter 2025 results: kr0.06 loss per share (further deteriorated from kr0.057 loss in 2Q 2024). Revenue: kr10.1m (down 34% from 2Q 2024). Net loss: kr14.9m (loss widened 14% from 2Q 2024). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. New Risk • Aug 21
New major risk - Revenue and earnings growth Earnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (kr29m net loss next year). Share price has been volatile over the past 3 months (8.7% average weekly change). Market cap is less than US$100m (kr106.0m market cap, or US$11.0m). Reported Earnings • May 09
First quarter 2025 earnings released: kr0.05 loss per share (vs kr0.046 loss in 1Q 2024) First quarter 2025 results: kr0.05 loss per share (further deteriorated from kr0.046 loss in 1Q 2024). Revenue: kr15.3m (up 20% from 1Q 2024). Net loss: kr12.3m (loss widened 17% from 1Q 2024). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. New Risk • May 08
New major risk - Revenue and earnings growth Earnings have declined by 18% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr126.7m market cap, or US$13.1m). Tillkännagivande • May 07
AroCell AB (publ) to Report Fiscal Year 2025 Results on Feb 24, 2026 AroCell AB (publ) announced that they will report fiscal year 2025 results on Feb 24, 2026 Tillkännagivande • Apr 11
Fredrik Lindgren Announces Not Stand for Re-Election to the Board of Arocell AB (Publ) AroCell AB (publ) announced Fredrik Lindgren has declined re-election to the board. Reported Earnings • Feb 20
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: kr0.18 loss per share (improved from kr0.26 loss in FY 2023). Revenue: kr57.4m (up 34% from FY 2023). Net loss: kr42.4m (loss narrowed 28% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 10%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Feb 19
AroCell AB (publ) to Report Fiscal Year 2024 Final Results on Apr 11, 2025 AroCell AB (publ) announced that they will report fiscal year 2024 final results on Apr 11, 2025 Tillkännagivande • Jan 09
AroCell AB (publ) Announces CFO Changes AroCell AB announced that Ellen Dittberner will return to her role as Chief Financial Officer (CFO) on January 13, 2025, after being on parental leave since February 2024. Ellen, who has previously played an important role in AroCell's financial development and strategic success, is now ready to resume her work and lead the company's financial function forward. During Ellen's parental leave, Lars Jakobsson has served as Acting CFO. Lars, with his extensive experience from both AroCell and IDL Biotech, has been an invaluable resource during this period. Tillkännagivande • Jan 03
Labbex Förvaltnings AB acquired additional 6.77% stake in AroCell AB (publ) (OM : AROC) Labbex Förvaltnings AB agreed to acquire additional 6.77% stake in AroCell AB (publ) (OM : AROC) on January 2, 2025. Post acquisition, Labbex Förvaltnings AB will hold 18.35 percent of the shares and votes in AroCell AB.
Labbex Förvaltnings AB completed acquistion of additional 6.77% stake in AroCell AB (publ) (OM : AROC) New Risk • Dec 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (kr91.7m market cap, or US$8.35m). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr37m net loss next year). Share price has been volatile over the past 3 months (8.1% average weekly change). Revenue is less than US$5m (kr52m revenue, or US$4.7m). New Risk • Nov 12
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr104.6m (US$9.64m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (kr104.6m market cap, or US$9.64m). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr37m net loss next year). Share price has been volatile over the past 3 months (7.5% average weekly change). Revenue is less than US$5m (kr52m revenue, or US$4.8m). Tillkännagivande • Oct 28
AroCell Announces New Study Published on the Prognostic Value of sTK1 in Prostate Cancer AroCell announced the publication of an important study in the European Urology Open Science journal. The study, led by Teemu Murtola at the University of Tampere in collaboration with scientists in Vienna and Budapest, reveals significant findings on the prognostic value of serum thymidine kinase 1 (sTK1) levels in patients with metastatic prostate cancer. Prostate cancer is the most common malignancy in men. While the Prostate Specific Antigen (PSA) serum biomarker is widely used for early detection of prostate cancer, it offers limited value for prediction of patient survival outcomes. Thymidine kinase 1 (TK1), an enzyme found in actively dividing cells, emerges as a crucial biomarker in this context. Different groups of patients with metastatic prostate cancer were studied with respect to the prognostic value of elevated levels of sTK1. High levels of sTK1 were associated with poor survival in patients with hormone-sensitive tumors treated with anti-hormone therapy. A more than 8-fold increased risk of death was associated with elevated sTK1, also after adjusting for age and other clinical factors, including PSA. A strong correlation between high sTK1 levels and reduced survival was also noted in castration-resistant prostate cancer patients. Interestingly, in patients treated with docetaxel (a chemotherapeutical drug), the association between sTK1 levels and survival was weaker compared to that observed for patients receiving androgen receptor signaling inhibitors. These results confirm previous findings of the potential of sTK1 as a prognostic biomarker. The findings suggest that sTK1 can be used to identify patients with disseminated prostate cancer that will benefit from chemotherapy rather than anti-hormonal treatment. Reported Earnings • Oct 26
Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.056 loss in 3Q 2023) Third quarter 2024 results: kr0.04 loss per share (improved from kr0.056 loss in 3Q 2023). Revenue: kr14.0m (up 31% from 3Q 2023). Net loss: kr9.84m (loss narrowed 24% from 3Q 2023). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 22
Second quarter 2024 earnings released: kr0.06 loss per share (vs kr0.067 loss in 2Q 2023) Second quarter 2024 results: kr0.06 loss per share (improved from kr0.067 loss in 2Q 2023). Revenue: kr15.3m (up 30% from 2Q 2023). Net loss: kr13.1m (loss narrowed 16% from 2Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. New Risk • Jul 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (kr45m net loss next year). Share price has been volatile over the past 3 months (8.6% average weekly change). Revenue is less than US$5m (kr45m revenue, or US$4.1m). Market cap is less than US$100m (kr110.1m market cap, or US$10.2m). Reported Earnings • May 05
First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.059 loss in 1Q 2023) First quarter 2024 results: kr0.05 loss per share (improved from kr0.059 loss in 1Q 2023). Revenue: kr12.8m (up 16% from 1Q 2023). Net loss: kr10.5m (loss narrowed 23% from 1Q 2023). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings. Tillkännagivande • May 05
AroCell AB (publ) to Report Q2, 2024 Results on Aug 21, 2024 AroCell AB (publ) announced that they will report Q2, 2024 results on Aug 21, 2024 Tillkännagivande • May 03
AroCell AB (publ), Annual General Meeting, May 22, 2024 AroCell AB (publ), Annual General Meeting, May 22, 2024. Tillkännagivande • Apr 13
AroCell AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025 AroCell AB (publ) announced that they will report fiscal year 2024 results on Feb 19, 2025 Buy Or Sell Opportunity • Apr 10
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 21% to kr0.34. The fair value is estimated to be kr0.43, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 91% in 2 years. Earnings are forecast to grow by 46% in the next 2 years. Buy Or Sell Opportunity • Mar 20
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 23% to kr0.34. The fair value is estimated to be kr0.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 91% in 2 years. Earnings are forecast to grow by 46% in the next 2 years. Reported Earnings • Feb 23
Full year 2023 earnings released: kr0.26 loss per share (vs kr0.27 loss in FY 2022) Full year 2023 results: kr0.26 loss per share. Revenue: kr43.0m (up 16% from FY 2022). Net loss: kr59.3m (flat on FY 2022). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Sweden. Tillkännagivande • Feb 23
AroCell AB (publ) to Report Q3, 2024 Results on Oct 24, 2024 AroCell AB (publ) announced that they will report Q3, 2024 results on Oct 24, 2024 Tillkännagivande • Feb 02
AroCell AB (publ) Announces Chief Financial Officer Changes AroCell AB (publ) announced that Ellen Dittberner will be on parental leave from her position as Chief Financial Officer (CFO) starting on February 1, 2024. During this period, Lars Jakobsson will serve as the acting CFO. Lars has previously held the position of CFO at IDL Biotech and AroCell AB from 2017 to 2022. Major Estimate Revision • Nov 09
Consensus revenue estimates fall by 12% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr51.3m to kr45.1m. Forecast losses increased from -kr0.30 to -kr2.00 per share. Life Sciences industry in Sweden expected to see average net income growth of 15% next year. Consensus price target down from kr2.90 to kr1.30. Share price fell 5.7% to kr0.48 over the past week. Reported Earnings • Nov 03
Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.048 loss in 3Q 2022) Third quarter 2023 results: kr0.06 loss per share (further deteriorated from kr0.048 loss in 3Q 2022). Revenue: kr10.7m (up 2.9% from 3Q 2022). Net loss: kr13.0m (loss widened 18% from 3Q 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. New Risk • Oct 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr108.5m (US$9.72m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (kr108.5m market cap, or US$9.72m). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr52m net loss next year). Revenue is less than US$5m (kr46m revenue, or US$4.1m). Tillkännagivande • Sep 19
AroCell AB (Publ) Announces New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian Cancer AroCell AB (publ) announced that its recent study on different clinical applications of the TK 210 ELISA in ovarian cancer has been accepted for publication in the Karger Oncology journal. The study focused on demonstrating the clinical utility of TK1-specific activity (TK1 SA) in the early detection of ovarian cancer. This study was conducted in collaboration with Professor Josko Osredkar and is titled "Clinical Significance of the TK1 specific Activity in the Early Detection of Ovarian Cancer". TK1 SA is determined by calculating the ratio of TK1 activity by TK-Liaison and TK1 protein by AroCell TK 210 ELISA. The study included 134 patients with ovarian tumors (72 benign and 62 malignant) and 64 healthy age-matched controls. The study results revealed that TK1 SA, which complements traditional biomarkers such as CA 125 and HE4, significantly improved the sensitivity for early detection of benign and malignant ovarian cancer. The combination of various biomarkers provided a more comprehensive and accurate diagnostic approach. These findings have implications in proving the early detection rates and subsequent treatment outcomes for ovarian cancer patients. Furthermore, the study observed the fluctuations in TK1 SA levels in relation to surgery and Chemotherapy which provided valuable information for monitoring the effectiveness of treatment and assessing disease progression. New Risk • Aug 25
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr109.4m (US$9.89m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (kr109.4m market cap, or US$9.89m). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr52m net loss next year). Revenue is less than US$5m (kr46m revenue, or US$4.1m). Reported Earnings • Aug 23
Second quarter 2023 earnings released: kr0.067 loss per share (vs kr0.069 loss in 2Q 2022) Second quarter 2023 results: kr0.067 loss per share (improved from kr0.069 loss in 2Q 2022). Revenue: kr11.8m (up 86% from 2Q 2022). Net loss: kr15.5m (loss narrowed 2.6% from 2Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings. Reported Earnings • May 04
First quarter 2023 earnings released: kr0.06 loss per share (vs kr0.091 loss in 1Q 2022) First quarter 2023 results: kr0.06 loss per share (improved from kr0.091 loss in 1Q 2022). Revenue: kr11.1m (up 42% from 1Q 2022). Net loss: kr13.7m (loss narrowed 12% from 1Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 24
Full year 2022 earnings released: kr0.28 loss per share (vs kr0.53 loss in FY 2021) Full year 2022 results: kr0.28 loss per share. Revenue: kr37.0m (up 208% from FY 2021). Net loss: kr59.0m (loss widened 18% from FY 2021). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Sweden. Price Target Changed • Nov 16
Price target decreased to kr2.30 Down from kr3.50, the current price target is provided by 1 analyst. New target price is 297% above last closing price of kr0.58. Stock is down 70% over the past year. The company is forecast to post a net loss per share of kr0.50 next year compared to a net loss per share of kr0.53 last year. Board Change • Nov 16
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Independent Director Eva Nordström is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Major Estimate Revision • Nov 03
Consensus revenue estimates increase by 17% The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from kr30.0m to kr35.0m. Forecast losses expected to reduce from -kr0.60 to -kr0.50 per share. Life Sciences industry in Sweden expected to see average net income growth of 23% next year. Consensus price target of kr2.30 unchanged from last update. Share price rose 11% to kr0.61 over the past week. Reported Earnings • Nov 02
Third quarter 2022 earnings released: kr0.05 loss per share (vs kr0.15 loss in 3Q 2021) Third quarter 2022 results: kr0.05 loss per share (improved from kr0.15 loss in 3Q 2021). Revenue: kr10.4m (up 73% from 3Q 2021). Net loss: kr11.1m (loss narrowed 37% from 3Q 2021). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 19
Second quarter 2022 earnings released: kr0.07 loss per share (vs kr0.089 loss in 2Q 2021) Second quarter 2022 results: kr0.07 loss per share. Revenue: kr6.35m (up kr6.32m from 2Q 2021). Net loss: kr15.9m (loss widened 136% from 2Q 2021). Over the next year, revenue is forecast to grow 46%, compared to a 11% growth forecast for the Life Sciences industry in Sweden. Tillkännagivande • Aug 18
AroCell AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023 AroCell AB (publ) announced that they will report fiscal year 2022 results on Feb 23, 2023 Board Change • Jun 02
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Director Eva Nordström is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Recent Insider Transactions • May 13
Chief Executive Officer recently bought kr221k worth of stock On the 9th of May, Anders Hultman bought around 460k shares on-market at roughly kr0.48 per share. This was the largest purchase by an insider in the last 3 months. Anders has been a buyer over the last 12 months, purchasing a net total of kr305k worth in shares. Reported Earnings • May 03
First quarter 2022 earnings released: kr0.09 loss per share (vs kr0.08 loss in 1Q 2021) First quarter 2022 results: kr0.09 loss per share (down from kr0.08 loss in 1Q 2021). Net loss: kr15.5m (loss widened 155% from 1Q 2021). Over the next year, revenue is forecast to grow 57%, compared to a 18% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Price Target Changed • Apr 27
Price target decreased to kr2.00 Down from kr3.50, the current price target is provided by 1 analyst. New target price is 294% above last closing price of kr0.51. Stock is down 92% over the past year. The company is forecast to post a net loss per share of kr0.60 next year compared to a net loss per share of kr0.53 last year. Board Change • Apr 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Per-Anders Abrahamsson was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 08
Full year 2021 earnings released: kr0.54 loss per share (vs kr0.33 loss in FY 2020) Full year 2021 results: kr0.54 loss per share (down from kr0.33 loss in FY 2020). Net loss: kr50.0m (loss widened 108% from FY 2020). Over the next year, revenue is forecast to grow 133%, compared to a 25% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Board Change • Feb 04
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Per-Anders Abrahamsson was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Sep 22
Head of Operations recently bought kr81k worth of stock On the 20th of September, Filip Fogdestam bought around 50k shares on-market at roughly kr1.62 per share. This was the largest purchase by an insider in the last 3 months. Filip has been a buyer over the last 12 months, purchasing a net total of kr172k worth in shares. Reported Earnings • May 17
First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.086 loss in 1Q 2020) First quarter 2021 results: Net loss: kr6.08m (loss widened 11% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Executive Departure • May 01
Chief Commercial Officer has left the company On the 30th of April, Michael Brobjer's tenure as Chief Commercial Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Michael's name. Michael is the only executive to leave the company over the last 12 months. Is New 90 Day High Low • Mar 09
New 90-day high: kr3.41 The company is up 38% from its price of kr2.48 on 09 December 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 35% over the same period. Reported Earnings • Feb 21
Full year 2020 earnings released: kr0.33 loss per share (vs kr0.53 loss in FY 2019) Full year 2020 results: Net loss: kr24.1m (loss widened 16% from FY 2019). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Jan 26
Head of Operations recently bought kr91k worth of stock On the 18th of January, Filip Fogdestam bought around 35k shares on-market at roughly kr2.59 per share. This was the largest purchase by an insider in the last 3 months. This was Filip's only on-market trade for the last 12 months. Recent Insider Transactions • Jan 20
Head of Operations recently bought kr91k worth of stock On the 18th of January, Filip Fogdestam bought around 35k shares on-market at roughly kr2.59 per share. This was the largest purchase by an insider in the last 3 months. This was Filip's only on-market trade for the last 12 months. Is New 90 Day High Low • Oct 26
New 90-day low: kr2.43 The company is down 33% from its price of kr3.64 on 28 July 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 21% over the same period. 
